Human-centric preclinical models for CAR T cell therapy in solid tumors: Where patient-derived organoids fit.

Patient-derived organoids (PDOs) effectively preserve human tumor features, enabling functional evaluation of CAR T cell targets and resistance mechanisms in solid tumors.

• Why it matters: Current preclinical models do not fully capture human tumor biology, limiting the translational progress of CAR T cell therapy for solid tumors. Improving these models is crucial for advancing treatment development.
• What they did: Researchers highlight how PDOs retain cellular heterogeneity and tissue architecture, supporting the assessment of CAR T cell targets, resistance, safety, and next-generation approaches in preclinical studies.
• The result: Using PDOs may enhance the development and evaluation of CAR T cell therapies for solid tumors, potentially accelerating their translation into clinical applications.